Literature DB >> 21941090

Recent developments for Pseudomonas vaccines.

Anurag Sharma1, Anja Krause, Stefan Worgall.   

Abstract

Infections with Pseudomonas aeruginosa are a major health problem for immune-compromised patients and individuals with cystic fibrosis. A vaccine against: P. aeruginosa has long been sought after, but is so far not available. Several vaccine candidates have been assessed in experimental animals and humans, which include sub-cellular fractions, capsule components, purified and recombinant proteins. Unique characteristics of the host and the pathogen have complicated the vaccine development. This review summarizes the current state of vaccine development for this ubiquitous pathogen, in particular to provide mucosal immunity against infections of the respiratory tract in susceptible individuals with cystic fibrosis.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21941090      PMCID： PMC3360073          DOI： 10.4161/hv.7.10.16369

Source DB:  PubMed          Journal:  Hum Vaccin        ISSN： 1554-8600


  226 in total

1.  Development of a preventive vaccine for Ebola virus infection in primates.

Authors:  N J Sullivan; A Sanchez; P E Rollin; Z Y Yang; G J Nabel
Journal:  Nature       Date:  2000-11-30       Impact factor: 49.962

2.  Human immune response to a Pseudomonas aeruginosa outer membrane protein vaccine.

Authors:  I J Jang; I S Kim; W J Park; K S Yoo; D S Yim; H K Kim; S G Shin; W H Chang; N G Lee; S B Jung; D H Ahn; Y J Cho; B Y Ahn; Y Lee; Y G Kim; S W Nam; H S Kim
Journal:  Vaccine       Date:  1999-01       Impact factor: 3.641

3.  Advantages of a synthetic peptide immunogen over a protein immunogen in the development of an anti-pilus vaccine for Pseudomonas aeruginosa.

Authors:  Daniel J Kao; Robert S Hodges
Journal:  Chem Biol Drug Des       Date:  2009-07       Impact factor: 2.817

4.  Immunization of noncolonized cystic fibrosis patients against Pseudomonas aeruginosa.

Authors:  S J Cryz; J Wedgwood; A B Lang; A Ruedeberg; J U Que; E Fürer; U B Schaad
Journal:  J Infect Dis       Date:  1994-05       Impact factor: 5.226

5.  Immunization with a Pseudomonas aeruginosa 1244 pilin provides O-antigen-specific protection.

Authors:  Joseph Horzempa; Thomas K Held; Alan S Cross; Dana Furst; Mohammed Qutyan; Alice N Neely; Peter Castric
Journal:  Clin Vaccine Immunol       Date:  2008-02-13

6.  Human monoclonal antibodies that protect mice against challenge with Pseudomonas aeruginosa.

Authors:  H J Zweerink; M C Gammon; C F Hutchison; J J Jackson; D Lombardo; K M Miner; J M Puckett; T J Sewell; N H Sigal
Journal:  Infect Immun       Date:  1988-08       Impact factor: 3.441

7.  Characterization of the human immune response to a Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine.

Authors:  S J Cryz; J C Sadoff; D Ohman; E Fürer
Journal:  J Lab Clin Med       Date:  1988-06

8.  Immunization with a Pseudomonas aeruginosa immunotype 5 O polysaccharide-toxin A conjugate vaccine: effect of a booster dose on antibody levels in humans.

Authors:  S J Cryz; J C Sadoff; E Fürer
Journal:  Infect Immun       Date:  1988-07       Impact factor: 3.441

9.  Effects of a human antiflagellar monoclonal antibody in combination with antibiotics on Pseudomonas aeruginosa infection.

Authors:  I Uezumi; M Terashima; T Kohzuki; M Kato; K Irie; H Ochi; H Noguchi
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

10.  Recombinant OprF-OprI as a vaccine against Pseudomonas aeruginosa infections.

Authors:  U Baumann; E Mansouri; B-U von Specht
Journal:  Vaccine       Date:  2004-02-17       Impact factor: 3.641
View more
  37 in total

1.  Vaccine strategies against cystic fibrosis pathogens.

Authors:  Vincent Le Moigne; Jean-Louis Gaillard; Jean-Louis Herrmann
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

2.  Immunological considerations in the development of Pseudomonas aeruginosa vaccines.

Authors:  Sarah M Baker; James B McLachlan; Lisa A Morici
Journal:  Hum Vaccin Immunother       Date:  2019-09-05       Impact factor: 3.452

3.  Post-exposure immunization by capsid-modified AdC7 vector expressing Pseudomonas aeruginosa OprF clears P. aeruginosa respiratory infection.

Authors:  Rika Gomi; Anurag Sharma; Wenzhu Wu; Biin Sung; Stefan Worgall
Journal:  Vaccine       Date:  2017-11-07       Impact factor: 3.641

4.  PLGA-encapsulation of the Pseudomonas aeruginosa PopB vaccine antigen improves Th17 responses and confers protection against experimental acute pneumonia.

Authors:  Matthew M Schaefers; Biyan Duan; Boaz Mizrahi; Roger Lu; Gally Reznor; Daniel S Kohane; Gregory P Priebe
Journal:  Vaccine       Date:  2018-10-09       Impact factor: 3.641

Review 5.  Recent perspectives on the molecular basis of biofilm formation by Pseudomonas aeruginosa and approaches for treatment and biofilm dispersal.

Authors:  Sinosh Skariyachan; Vaishnavi Sneha Sridhar; Swathi Packirisamy; Supreetha Toplar Kumargowda; Sneha Basavaraj Challapilli
Journal:  Folia Microbiol (Praha)       Date:  2018-01-19       Impact factor: 2.099

Review 6.  Pushing beyond the Envelope: the Potential Roles of OprF in Pseudomonas aeruginosa Biofilm Formation and Pathogenicity

Authors:  Erin K Cassin; Boo Shan Tseng
Journal:  J Bacteriol       Date:  2019-08-22       Impact factor: 3.490

7.  Mucosal and systemic antibody responses to potential Pseudomonas aeruginosa vaccine protein antigens in young children with cystic fibrosis following colonization and infection.

Authors:  Ryka Moore; Jennelle M Kyd; Rosemary Carzino; Davide Armstrong; Keith Grimwood; Diana C Otczyk; Allan W Cripps
Journal:  Hum Vaccin Immunother       Date:  2012-12-18       Impact factor: 3.452

Review 8.  Vaccines for Pseudomonas aeruginosa: a long and winding road.

Authors:  Gregory P Priebe; Joanna B Goldberg
Journal:  Expert Rev Vaccines       Date:  2014-02-27       Impact factor: 5.217

9.  RGD capsid modification enhances mucosal protective immunity of a non-human primate adenovirus vector expressing Pseudomonas aeruginosa OprF.

Authors:  A Krause; W Z Whu; J Qiu; D Wafadari; N R Hackett; A Sharma; R G Crystal; S Worgall
Journal:  Clin Exp Immunol       Date:  2013-08       Impact factor: 4.330

10.  A temporal examination of the planktonic and biofilm proteome of whole cell Pseudomonas aeruginosa PAO1 using quantitative mass spectrometry.

Authors:  Amber J Park; Kathleen Murphy; Jonathan R Krieger; Dyanne Brewer; Paul Taylor; Marc Habash; Cezar M Khursigara
Journal:  Mol Cell Proteomics       Date:  2014-02-16       Impact factor: 5.911
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.